Hannah L. Litwak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hannah L. Litwak has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Allen Bateman
University of Wisconsin-Madison Wisconsin State Laboratory of Hygiene
2 shared publications Brian Emery
National Center for Immunization and Respiratory Disease, US Centers for Disease Control and Prevention Atlanta Georgia USA
2 shared publicationsCaelin Cubenas
National Center for Immunization and Respiratory Disease, US Centers for Disease Control and Prevention Atlanta Georgia USA
2 shared publicationsCarlos M. Perez
Wisconsin Division of Public Health Wisconsin Department of Health Services Madison Wisconsin USA
2 shared publicationsCria O. Gregory
National Center for Immunization and Respiratory Disease, US Centers for Disease Control and Prevention Atlanta Georgia USA
2 shared publicationsKyley Anhalt
Wisconsin State Laboratory of Hygiene Madsion Wisconsin USA
2 shared publications
Latest Publications
- Open Access
- 27 March 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (4) , e70879
Diversity of Rhinovirus and Enterovirus Infections Among Pediatric Patients Hospitalized in Wisconsin, 2022–2023
Severe rhinovirus (RV)/enterovirus (EV) respiratory infections in pediatric patients increased in the US during 2022–2023. This study aimed to characterize RV/EV genetic diversity among hospitalized children in Wisconsin and describe demographic and clinical factors of patients by RV/EV type. During September 2022–April 2023, five Wisconsin pediatric hospitals submitted five RV/EV‐positive specimens weekly to CDC. Viral typing was performed using partial viral protein (VP) 4/VP2 (RV) and VP1 (EV) sequencing. Wisconsin Department of Health Services abstracted demographic, comorbid condition, and hospitalization course information from patient medical records. Ninety‐six patients were included in this investigation. RV‐C ( n = 40, 42%) and RV‐A ( n = 31, 32%) were the most frequently detected species, with 46 RV and 5 EV types identified. The median age was 2.5 (IQR: 0.7–5.5) years. Seventy‐one (74%) children had at least one comorbid condition. Asthma was more common among children with RV‐C infections ( n = 12, 30%) compared with other RVs ( n = 3, 9%) ( p = 0.02). RV‐A and RV‐C were important contributors to severe pediatric respiratory infection in Wisconsin. Molecular typing showed virus divergence typically observed during season‐long investigations. Year‐round molecular characterization is needed to better understand the contribution of RV/EV types to severe pediatric respiratory illness.
- 27 March 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (4) , e70879
Open AccessDiversity of Rhinovirus and Enterovirus Infections Among Pediatric Patients Hospitalized in Wisconsin, 2022–2023
Severe rhinovirus (RV)/enterovirus (EV) respiratory infections in pediatric patients increased in the US during 2022–2023. This study aimed to characterize RV/EV genetic diversity among hospitalized children in Wisconsin and describe demographic and clinical factors of patients by RV/EV type. During September 2022–April 2023, five Wisconsin pediatric hospitals submitted five RV/EV‐positive specimens weekly to CDC. Viral typing was performed using partial viral protein (VP) 4/VP2 (RV) and VP1 (EV) sequencing. Wisconsin Department of Health Services abstracted demographic, comorbid condition, and hospitalization course information from patient medical records. Ninety‐six patients were included in this investigation. RV‐C ( n = 40, 42%) and RV‐A ( n = 31, 32%) were the most frequently detected species, with 46 RV and 5 EV types identified. The median age was 2.5 (IQR: 0.7–5.5) years. Seventy‐one (74%) children had at least one comorbid condition. Asthma was more common among children with RV‐C infections ( n = 12, 30%) compared with other RVs ( n = 3, 9%) ( p = 0.02). RV‐A and RV‐C were important contributors to severe pediatric respiratory infection in Wisconsin. Molecular typing showed virus divergence typically observed during season‐long investigations. Year‐round molecular characterization is needed to better understand the contribution of RV/EV types to severe pediatric respiratory illness.
- Open Access
- 1 September 2025
- Published by Wiley
Diversity of Rhinovirus and Enterovirus Infections Among Pediatric Patients Hospitalized in Wisconsin, 2022-2023
Severe rhinovirus (RV)/enterovirus (EV) respiratory infections in pediatric patients increased in the US during 2022-2023. This study aimed to characterize RV/EV genetic diversity among hospitalized children in Wisconsin and describe demographic and clinical factors of patients by RV/EV type. During September 2022–April 2023, five Wisconsin pediatric hospitals submitted five RV/EV-positive specimens weekly to CDC. Viral typing was performed using partial viral protein (VP) 4/VP2 (RV) and VP1 (EV) sequencing. Wisconsin Department of Health Services abstracted demographic, comorbid condition, and hospitalization course information from patient medical records. Ninety-six patients were included in this investigation. RV-C (n=40, 42%) and RV-A (n=31, 32%) were the most frequently detected species, with 46 RV and 5 EV types identified. The median age was 2.5 (IQR: 0.7-5.5) years. Seventy-one (74%) children had at least one comorbid condition. Asthma was more common among children with RV-C infections (n=12, 30%) compared with other RVs (n=3, 9%) (p=0.02). RV-A and RV-C were important contributors to severe pediatric respiratory infection in Wisconsin. Molecular typing showed virus divergence typically observed during season-long investigations. Year-round molecular characterization is needed to better understand the contribution of RV/EV types to severe pediatric respiratory illness.
- 1 September 2025
- Published by Wiley
Open AccessDiversity of Rhinovirus and Enterovirus Infections Among Pediatric Patients Hospitalized in Wisconsin, 2022-2023
Severe rhinovirus (RV)/enterovirus (EV) respiratory infections in pediatric patients increased in the US during 2022-2023. This study aimed to characterize RV/EV genetic diversity among hospitalized children in Wisconsin and describe demographic and clinical factors of patients by RV/EV type. During September 2022–April 2023, five Wisconsin pediatric hospitals submitted five RV/EV-positive specimens weekly to CDC. Viral typing was performed using partial viral protein (VP) 4/VP2 (RV) and VP1 (EV) sequencing. Wisconsin Department of Health Services abstracted demographic, comorbid condition, and hospitalization course information from patient medical records. Ninety-six patients were included in this investigation. RV-C (n=40, 42%) and RV-A (n=31, 32%) were the most frequently detected species, with 46 RV and 5 EV types identified. The median age was 2.5 (IQR: 0.7-5.5) years. Seventy-one (74%) children had at least one comorbid condition. Asthma was more common among children with RV-C infections (n=12, 30%) compared with other RVs (n=3, 9%) (p=0.02). RV-A and RV-C were important contributors to severe pediatric respiratory infection in Wisconsin. Molecular typing showed virus divergence typically observed during season-long investigations. Year-round molecular characterization is needed to better understand the contribution of RV/EV types to severe pediatric respiratory illness.